• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
High-Growth Diagnostic Testing Markets - Product Image

High-Growth Diagnostic Testing Markets

  • ID: 301884
  • November 2013
  • Region: Global
  • 466 Pages
  • TriMark Publications

FEATURED COMPANIES

  • A Menarini Diagnostics
  • Ani Biotech Oy Ltd
  • Bio-Rad Laboratories, Inc
  • Genzyme Diagnostics
  • LifeScan
  • OraSure
  • MORE

There will be a steady increase in demand for new diagnostic testing services in the next five-year period, along with pressures to improve the quality of healthcare delivered in the clinic and also to lower its costs. Clinical labs experienced a substantial growth during the last decade.

The emphasis in this report is on those companies that are actively developing and marketing high-growth diagnostic testing technologies in the clinical hospital market. It defines the dollar volume of sales, both worldwide and in the U.S., of the market and analyzes the factors that influence the size and growth of market segments. The study goes on to discuss in detail trends that have developed which have stimulated this market, and also comments in detail patterns of information processing in the high-growth diagnostic testing technologies.

Moreover, this exanimation provides an overview of the diagnostic testing market, including the latest information regarding exciting new products and industry trends. It will not only quantify but also qualify the market high-growth segments as an area of research and investment. Forecasts of the market and analyses of products in the worldwide prescriptions market will provide a basis for understanding the significance of past developments and future possibilities within this therapeutic category.

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • A Menarini Diagnostics
  • Ani Biotech Oy Ltd
  • Bio-Rad Laboratories, Inc
  • Genzyme Diagnostics
  • LifeScan
  • OraSure
  • MORE

1. Overview
1.1 Statement of Report
1.2 Scope of This Report
1.3 Methodology
1.4 Executive Summary

2. Introduction to the High-Growth Testing Market
2.1 Introduction to the Global Diagnostic Market
2.2 General Areas with Potential for High-Growth Testing
2.3 Market Drivers in the High-Growth Diagnostics Testing Sector
2.4 Market Segments for High-Growth Testing
2.5 Key Players in the High-Growth Diagnostics Testing Segment
2.6 High-Growth Testing Sector Analysis

3. Hepatitis Serologic Markers and Nucleic Acid Testing
3.1 Hepatitis B Virus (HBV)
3.2 Major Suppliers of Hepatitis B Virus (HBV) Testing Products
3.3 Market Revenue Analysis
3.4 Hepatitis C Virus (HCV) Testing
3.5 Market Revenue Analysis
3.6 Market Share Analysis

4. Human Papillomavirus (HPV) Testing
4.1 Overview
4.2 The Association of HPV and Cervical Cancer
4.3 The PAP Test
4.4 Current Laboratory Methods for HPV Detection
4.4.1 Direct-Probe Methods
4.4.2 Signal Amplification
4.4.3 Target Amplification
4.5 Assays for HPV
4.6 Market Revenue Analysis
4.7 Competitor Activity
4.8 Market and Technology Trends
4.8.1 Market Trends
4.8.2 Technology Trends

5. HIV
5.1 Introduction to HIV/AIDS
5.2 Statistical Data Global HIV/AIDS Epidemic
5.3 HIV Prevention and Treatment
5.3.1 HIV Prevention
5.3.2 HIV Treatment
5.4 U.S. Testing Market
5.5 Market Dynamics
5.5.1 Market Drivers
5.5.2 Market Restraints
5.5.3 Market Trends
5.5.4 Technology Trends
5.6 Review of Selected HIV Testing Devices
5.7 Market Revenue Analysis
5.8 Competitor Activity
5.9 HIV Market Challenges and Strategic Recommendations
5.10 Insurance Coverage and Reimbursement
5.11 Policies Affecting HIV Testing
5.12 Recent Industry Activity

6. Infectious Disease Testing
6.1 Introduction to Infectious Disease Testing
6.2 Types of Diagnosis for Infectious Diseases
6.2.1 Microbial Culture
6.2.2 Microscopy
6.2.3 Biochemical Tests
6.2.4 Molecular Diagnostics
6.3 Diagnostic Platforms for Infectious Diseases
6.3.1 Centralized Laboratory Testing for Infectious Diseases
6.3.2 POC Testing for Infectious Diseases
6.4 Emerging Technologies
6.5 Qualitative Analysis
6.5.1 Market Drivers
6.5.2 Market Restraints
6.6 Streptococcus Testing
6.7 Chlamydia Testing
6.8 Mononucleosis
6.9 Gonorrhea
6.10 Influenza
6.11 Malaria
6.12 Tuberculosis
6.13 Methicillin-Resistant Staphylococcus Aureus (MRSA)
6.14 Market Revenue Analysis

7. Cardiac Markers
7.1 Market Overview
7.2 Cardiac Marker Tests
7.2.1 Creatine Kinase (CK)
7.2.2 Myoglobin
7.2.3 Cardiac Troponins T (TnT), I (TnI) and C (TnC)
7.2.4 C-Reactive Protein (CRP)
7.2.5 Homocysteine
7.3 Emerging Markers
7.3.1 B-type Natriuretic Peptide (BNP)
7.3.2 Myeloperoxidase (MPO)
7.3.3 Ischemia Modified Albumin (IMA)
7.3.4 Glycogen Phosphorylase Isoenzyme BB (GPBB)
7.3.5 Fatty Acid-Binding Proteins (FABPs)
7.4 Qualitative Analysis
7.4.1 Market Drivers
7.4.2 Market Restraints
7.5 Specific Cardiac Conditions
7.5.1 Acute Myocardial Infarction
7.5.2 Heart Failure (BNP)
7.5.2.1 Market Overview
7.5.2.2 Commercial Assays for BNP and NT-proBNP
7.5.2.3 Clinical Applications of BNP
7.5.3 CRP
7.6 Pulmonary Embolism (D-dimer Test)
7.7 Key Players
7.8 Market Revenue Analysis

8. Cytogenetic Testing
8.1 Cancer Testing
8.2 Prenatal Testing and Cytogenetics
8.2.1 Cystic Fibrosis Testing
8.2.1.1 CF Testing Methodology
8.2.1.2 CF Screening Technology Summary
8.3 Key Players in Segment

9. Fertility Testing

10. Cancer Biomarker Testing
10.1 Segment Overview
10.2 The Cancer Testing Market
10.3 Competition
10.4 Individual Markets
10.4.1 Cancer Pathology: Testing
10.4.1.1 Rare Cell/Micro Metastasis Detection
10.4.1.2 Cancer Pathology: High-Throughput Screening
10.4.1.3 Competition
10.4.1.4 Drivers
10.4.2 Breast Cancer
10.4.2.1 CA 15-3
10.4.2.2 CA 27-29
10.4.2.3 BRCA1 and BRCA2 Breast and Ovarian Cancer Genes
10.4.2.4 Estrogen and Progesterone Receptor (ER and PR)
10.4.2.5 Human Epidermal Growth Factor Receptor 2 (HER-2)
10.4.2.6 Herceptin
10.4.2.7 p53
10.4.2.8 Nuclear Matrix Protein 66 (NMP66)
10.4.2.9 Mammastatin
10.4.2.10 Drivers for Breast Cancer Test Development
10.4.3 Ovarian Cancer
10.4.3.1 Cancer Antigen 125 (CA 125)
10.4.3.2 BRCA1 and BRCA2
10.4.3.3 Steroid Hormone Receptors
10.4.3.4 Epidermal Growth Factor Receptor (EGFR)
10.4.3.5 Lysophospholipids
10.4.4 Cervical Cancer
10.4.4.1 Cervical Cancer Screening Tests
10.4.5 Colon Cancer DNA Testing
10.5 Pharmacogenomic Cancer Testing
10.6 Market Revenue Analysis

11. Substance Abuse Testing
11.1 Background to POC Substance Abuse Testing
11.2 Substance Abuse Test Types
11.2.1 Urine Substance/Drug Screening
11.2.2 Hair Tests for Substance Abuse and Screening
11.2.3 Blood Tests for Substance Abuse and Screening
11.2.4 Saliva Tests for Substance Abuse and Screening
11.2.5 Sweat Tests for Substance Abuse and Screening
11.3 Alcohol Abuse and Screening
11.4 Saliva Testing
11.5 Qualitative Analysis
11.5.1 Market Drivers
11.5.2 Market Restraints
11.6 Review of Selected POC Substance Abuse Analyzers
11.7 Review of Company Products
11.7.1 Alere
11.7.2 Abbott Diagnostics
11.7.3 Roche Diagnostics
11.7.4 BioScan Screening Systems, Inc.
11.7.5 American Bio Medica Corp.
11.7.6 Phamatech, Inc.
11.7.7 First Check Medical
11.7.8 OraSure
11.7.9 Avitar, Inc.
11.7.10 Concateno (Alere, Inc.)
11.7.11 Pathtech
11.7.12 Alfa Scientific Designs, Inc.
11.7.13 TCPI, Inc.
11.7.14 Roche
11.7.15 Biophor Diagnostics
11.7.16 Randox Laboratories
11.7.17 Branan Medical
11.7.18 Concateno
11.8 Market Revenue Analysis

12. Vitamin D Diagnostic Testing
12.1 Market Revenue Analysis

13. Renal Dialysis Testing

14. Companion Diagnostics
14.1 Market Revenue Analysis

15. Summary Analysis of the Global IVD High-Growth Market by Geographic Region
15.1 Summary Analysis of the Global IVD Market
15.2 Summary Analysis of the Global IVD High-Growth Market by Geographic Region
15.3 U.S.: Summary Analysis of the IVD High-Growth Market
15.3.1 U.S.: Summary of IVD High-Growth Market
15.3.2 Cardiac Markers
15.4 Europe: Summary Analysis of the IVD High-Growth Market
15.4.1 Summary of IVD High-Growth Market Europe
15.5 Brazil: Summary Analysis of the IVD High-Growth Market
15.5.1 Summary of IVD High-Growth Market Brazil
15.6 Russia: Summary Analysis of the IVD High-Growth Market
15.6.1 Summary of IVD High-Growth Market Russia
15.7 India: Summary Analysis of the IVD High-Growth Market
15.7.1 Summary of IVD High-Growth Market India
15.8 China: Summary Analysis of the IVD High-Growth Market
15.8.1 Summary of IVD High-Growth Market China
15.9 South-East Asia and Japan: Summary Analysis of the IVD High-Growth Market
15.9.1 Japan
15.9.2 South Korea
15.9.3 Rapid Growth Market of IVD HIV/AIDS Testing in Other Asia
15.9.4 Summary of IVD High-Growth Market Other Asia

16. Clinical Laboratory Genomics
16.1 Introduction
16.2 Clinical Laboratory Genomics Testing
16.3 Developments in Clinical Laboratory Genomics
16.3.1 Nucleic Acid Amplification Techniques
16.3.2 Chromosome Imaging
16.3.3 Genomics Technologies
16.3.4 Proteomics Technology
16.3.5 Current Pharmacogenomic Tests
16.3.6 Future Pharmacogenomic Testing

17. Cellular Imaging Cytopathology and Histopathology
17.1 Segment Overview
17.2 The Market
17.3 Market Drivers
17.4 Market Restraints
17.5 Cytology and Histology Technology Platforms
17.5.1 Cytology Screening Procedures and Pap Smear Technology
17.5.2 Histology
17.5.3 Market Drivers
17.5.4 ISH Staining
17.5.5 Special-Stains Staining
17.6 Third-Party Reimbursement
17.7 Competition

18. High-Growth Testing Diagnostic Trends
18.1 Genetic Testing
18.2 Quality Measures
18.3 Moderators of Growth
18.3.1 Diagnostics and the Aging Population
18.3.2 Individualized Medicine
18.3.3 Genetic Testing
18.4 Workforce Issues
18.5 Reimbursement
18.5.1 Cardiovascular
18.5.2 Screening for Diabetes
18.5.3 CPT Test Codes and Payment Amounts
18.6 Rapid Near-Patient Testing in Hospitals
18.7 Satellite Facilities
18.8 Regionalization of Laboratory Care
18.9 Requirements for High-Growth Testing
18.10 Clinical Laboratory Improvement Act (CLIA)

19. Important Technology Trends

20. Molecular Diagnostics a Major Diagnostic Technological Advance
20.1 Polymerase Chain Reaction (PCR)-based Molecular Diagnostics
20.2 Micrarray Technologies and Molecular Diagnostics
20.3 Isothermal Amplification Technologies and Molecular Diagnostics
20.4 Miniaturization Technologies and Molecular Diagnostics (Biochips and Lab on a Chip)

21. Technology Platform Innovations in POCT
21.1 Latest POCT Technological Platforms
21.1.1 Device Miniaturization and Microfluidic Technologies
21.1.2 Minimally-Invasive and Non-Invasive POCT Technologies
21.1.3 Advances in Wireless Technologies
21.1.4 Automation of POCT
21.1.5 Developments in New Genomic Technologies (Genotyping, Haplotyping and Sequencing
Technologies)
21.1.6 Advances in Informatics Technologies
21.1.7 Pharmacogenetic Testing
21.1.8 Multi Assay Technologies in POCT
21.2 Developments in Key Technologies
21.2.1 Medical and Biological Sensors and Sensor Systems
21.2.2 Recent Biosensor Product Introductions and Latest Innovative Developments
21.2.2.1 Nanoscale Sensors for the Detection of Cancer Biomarkers
21.2.2.2 ForteBio Introduces Dip and Read Protein G Biosensor for Octet Instruments
21.2.2.3 ForteBio Launches New Octet RED96 System and Dip and Read Protein L Biosensor
21.2.2.4 AgaMatrix Europe Limited Introduces the New Jazz Blood Glucose Meter in the U.K.
21.2.2.5 STMicroelectronics to Manufacture Worlds Smallest Biosensors
21.2.2.6 Universal Biosensors Advances Point of Care Molecular Diagnostic Opportunity
21.2.2.7 Clinitek Advantus—A Semi Automated Urine Analyzer for Point of Care Testing
21.2.2.8 The NOVA 16 STAT Chemistry Analyzer Offers the First All-Electrode-Based Seven Test Chemistry Profile
21.3 Sensor Systems for Diagnostic Applications
21.4 Nanogen (The ELITech Group) Third Generation Point of Care Analyzer
21.5 Philips Development of Magnotech Technology
21.6 Quidel Corporation MChip, AVR Chip and F Chip
21.7 Sanofi-Aventis

22. Data Management and Connectivity
22.1 Wireless LANs
22.2 Connectivity Platforms
22.2.1 DataLink Data Management System
22.2.2 RALS-Plus
22.2.2.1 International Technidyne Corporation HEMOCHRON Signature Elite
22.2.2.2 Siemens Diagnostics Rapidpoint Coag
22.2.2.3 Radiometer
22.2.2.4 HemoCue’s DM Hemoglobin
22.2.2.5 Roche Diagnostics
22.2.3 BD.id
22.2.4 Medical Implant Communications Service (MICS)
22.2.5 Conworx Technology
22.2.6 Lab Data Systems
22.2.7 Medasys
22.2.8 NoemaLife
22.3 Advantages of POCT Connectivity
22.3.1 Cost Benefit of POCT and IT Connectivity
22.3.2 Hospital Network Issues
22.4 POCT Analyzer Connectivity Software Solutions
22.5 POCT2-P

23. Biochips for Clinical Applications
23.1 Roche AmpliChip
23.2 Amersham CodeLink
23.3 Breast Cancer DNA Chips
23.4 Osmetech eSensor
23.5 Affymetrix GeneChip System 3000Dx v.2
23.6 Caliper and Cepheid
23.7 Agilent Technologies 2100 Lab-on-a-Chip

24. Company Profiles
24.1 Abaxis, Inc.
24.2 Abbott Laboratories
24.3 Accurex Biomedical Pvt. Ltd.
24.4 Adeza Biomedical Corporation (Hologic)
24.5 Agilent Technologies, Inc.
24.6 Alere, Inc.
24.7 Ambri Ltd.
24.8 American Bio Medica Corporation
24.9 Ani Biotech Oy Ltd.
24.10 Applied Spectral Imaging
24.11 Avitar, Inc.
24.12 Axis-Shield Plc
24.13 Bayer Corporation
24.14 Beckman Coulter (now part of Danaher)
24.15 Becton, Dickinson and Company
24.16 Biomerica, Inc.
24.17 Bio-Rad Laboratories, Inc.
24.18 Calypte Biomedical Corporation
24.19 Chembio Diagnostics, Inc.
24.20 Cozart Bioscience Ltd.
24.21 Denka Seiken Co., Ltd.
24.22 diaDexus, LLC
24.23 Enterix, Inc. (Subsidiary of Quest Diagnostics)
24.24 EY Laboratories, Inc.
24.25 Genetix (Molecular Devices)
24.26 Genzyme Diagnostics
24.27 Hologic Gen Probe
24.28 Instrumentation Laboratory (IL)/Werfen Group
24.29 Jiangnan Biotech
24.30 Johnson & Johnson
24.31 Kyowa Medex Co., Ltd.
24.32 LifeAssays AB
24.33 LifeScan
24.34 Matritech
24.35 A Menarini Diagnostics
24.36 Meretek Diagnostics Group (Otsuka Pharmaceutical, Inc.)
24.37 Meridian Bioscience
24.38 Medix Biochemica
24.39 Myriad Genetics, Inc.
24.40 NOVA Biomedical
24.41 OraSure
24.42 Pheromone Sciences Corporation
24.43 Polymedco, Inc.
24.44 Polymer Technology Systems, Inc.
24.45 QIAGEN N.V.
24.46 Quest Diagnostics, Inc.
24.47 Quidel Corporation
24.48 Radiometer Medical
24.49 Roche Diagnostics
24.50 Shanghai SIIC Kehua Biotech Co., Ltd. (Kehua Biotech)
24.51 Shionogi & Co., Ltd.
24.52 Siemens Healthcare Diagnostics
24.53 Spectral Diagnostics, Inc.
24.54 Trinity Biotech Plc
24.55 Väsamed, Inc.

Index of Figures

Figure 1.1: Worldwide Geographic Distribution of Total IVD Testing Market, 2012
Figure 1.2: Top 13 Country IVD Testing Markets, 2012
Figure 1.3: Company Market Share for IVD Testing Markets, 2012
Figure 3.1: Geographic Distribution of Chronic HBV Infection
Figure 3.2: Evolution of HBV Markers in Acute and Chronic Infection
Figure 3.3: U.S. Market Share of HCV Molecular Diagnostic Market, 2012
Figure 3.4: Global Market Share (Excluding U.S.) of HCV Molecular Diagnostic Market, 2012
Figure 4.1: PCR Analytical Sensitivity Detection Limits
Figure 4.2: The Basic Steps of Hybrid Capture 2 Technology
Figure 4.3: Diagram of Qiagen QIAsymphony SP/AS instrument
Figure 5.1: Global View of HIV Infection, 2009
Figure 5.2: Global Trend of HIV Infection, 1991-2011
Figure 5.3: Number of People Living with HIV, Newly Infected with HIV and Number of AIDS Deaths in the World, 1990-2011
Figure 5.4: Worldwide Rate of New HIV Cases, 1990-2011
Figure 5.5: Number of People Receiving Antiretroviral Therapy in Low- and Middle-Income Countries, by Region, 2003-2012 (with Projection)
Figure 6.1: U.S. and Outlying Areas Gonorrhea Infection Rates, 1941-2011
Figure 6.2: Global Incidence of Malaria
Figure 6.3: Mode of Action of Common Malaria RDT Format
Figure 6.4: Rate of Tuberculosis (TB) Cases by State/Area in the U.S., 2011
Figure 6.5: FIND Pipeline for TB Diagnostics
Figure 10.1: Cervical Cancer: 2008 Estimates: World Age-Standardized Incidence Rates per 100,000 Population, Females, World Regions
Figure 15.1: Worldwide Geographic Distribution of Total IVD Testing Market, 2012
Figure 15.2: Top 13 Country IVD Testing Markets, 2012
Figure 15.3: Company Market Share for IVD Testing Markets, 2012
Figure 15.4: Indian Diagnostics Market Segments, 2011
Figure 15.5: The Chinese Healthcare System
Figure 17.1: Worldwide Incidence Rates of Cervical Cancer Per 100,000 Females, 2011
Figure 17.2: Cervical Cancer: 2008 Estimates: World Age-Standardized Incidence Rates per 100,000 Population, Females, World Regions

Index of Tables

Table 1.1: Emerging Technology Platforms Driving High-Growth Diagnostics Market Segments
Table 1.2: Market Trends in the High-Growth Diagnostics Space
Table 1.3: Worldwide Geographic Distribution of Total IVD Testing Market, 2012
Table 1.4: Top 13 Country IVD Testing Markets, 2012
Table 1.5: Company Market Share for IVD Testing Markets, 2012
Table 1.6: Global Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing, 2008-2018
Table 1.7: Global IVD High-Growth Markets Revenues by Market Segment, 2008-2018
Table 1.8: Global IVD High-Growth Markets Percentage of Revenues by Geographic Region, 2008-2018
Table 1.9: Global IVD High-Growth Markets Percentage of Revenues by Product Type, 2008-2018
Table 3.1: Serological Diagnosis of Hepatitis B Virus Infections
Table 3.2: Lower Detection Limits of HBV DNA Assays
Table 3.3: Summary of Selected Suppliers of Hepatitis B Virus (HBV) Diagnostic Products by Technology
Table 3.4: Global Revenue Forecasts for Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Diagnostic Testing, 2008-2018
Table 3.5: Global Revenue Forecasts for Hepatitis B Virus (HBV) Diagnostic Testing, 2008-2018
Table 3.6: Efficiency of Available HCV Screening Tests
Table 3.7: Recommendations for Diagnostic Testing for Hepatitis C
Table 3.8: Hepatitis C Statistics
Table 3.9: Novartis Diagnostics Clinical Diagnostic Products Test for the Detection of HCV
Table 3.10: Global Revenue Forecasts for Hepatitis C Virus (HCV) Diagnostic Testing, 2008-2018
Table 3.11: Major Companies Marketing HCV Molecular Diagnostic Tests: Market Size and Share, 2012
Table 4.1: HPV Risk Factors
Table 4.2: HPV and Cervical Carcinoma
Table 4.3: Key Statistics on Cervical Cancer in the World, 2011
Table 4.4: Deaths in Thousands from Cervical Cancer by Region and by Age Group in 2011
Table 4.5: Reflex HPV Testing with Cytology
Table 4.6: Predictability of HPV Test by Abnormal Pap Smear Type
Table 4.7: Qiagen’s Digene HC2 High-Risk HPV DNA Test
Table 4.8: Commercially Available Molecular Diagnostic Products for HPV Assay
Table 4.9: Long-Term Trends in HPV Testing
Table 4.10: Global Revenue Forecasts for Human Papillomavirus (HPV) Diagnostic Testing, 2008-2018
Table 5.1: Global HIV Statistics, 2011
Table 5.2: Antiretroviral Therapy in Low- and Middle-Income Countries by Region, December 2011
Table 5.3: Diagnosis of HIV Infection in 2011 for the U.S. and Six Dependent Areas
Table 5.4: Estimated Number of AIDS Infection, 2011
Table 5.5: Drivers of Demand for HIV Diagnostic Testing
Table 5.6: NAT HIV Monitoring Market: Market Drivers Ranked in Order of Impact
Table 5.7: Drivers of Demand for HIV Diagnostic Testing
Table 5.8: NAT HIV Monitoring Market: Market Restraints Ranked in Order of Impact
Table 5.9: Selected POC Infectious Disease Testing Devices, 2011
Table 5.10: Commercially Available Molecular Diagnostic Products for HIV Assay
Table 5.11: Global Revenue Forecasts for HIV and AIDS Diagnostic Testing, 2008-2018
Table 5.12: Competitive Factors Related to HIV Tests
Table 6.1: Rapid Strep Tests on the Market
Table 6.2: U.S. Chlamydia Infection Rates, 1985-2011
Table 6.3: Rapid Tests for Chlamydia
Table 6.4: Rapid Tests for Gonorrhea
Table 6.5: Commercially-available Rapid Tests for Malaria
Table 6.6: Estimated TB Incidence, Prevalence and Mortality, 2011
Table 6.7: FIND Partners
Table 6.8: Global Market Potential for TB Diagnostic Testing, 2000-2012
Table 6.9: MRSA Diagnostics Currently on the Market
Table 6.10: Global Revenue Infectious Disease Revenue Analysis, 2008-2018
Table 7.1: Medication Chart for Cardiovascular Disease
Table 7.2: BNP Clinical Characteristics
Table 7.3: Cardiovascular Risk Classification by CRP Level
Table 7.4: Clinical Characteristics of D-dimer
Table 7.5: Global Revenue Forecasts for Cardiac Marker Testing, 2008-2018
Table 8.1: Genetic Testing: Consequences and Challenges
Table 8.2: CF Carrier Risk by Ethnic Group
Table 8.3: Reasons for CF Testing
Table 8.4: CF Gene Detection Rates Vary by Ethnic Background
Table 8.5: Global Market for CF Diagnostic Testing, 2008-2018
Table 8.6: U.S. Market for CF Diagnostic Testing, 2008-2018
Table 8.7: Commercial CF Screening Products
Table 8.8: Emerging CF Screening Products
Table 9.1: The Fertility Testing Market in the U.S., 2008-2018
Table 10.1: Organ-Specific Medicines in Development for Cancer
Table 10.2: Estimates for the Leading Sites of New Cancer Cases in the U.S. by Gender, 2013
Table 10.3: Estimates for the Leading Sites of Cancer Deaths in the U.S. by Gender, 2013
Table 10.4: Worldwide Number of New Cancer Cases and Deaths by Type of Cancer in Men
Table 10.5: Worldwide Number of New Cancer Cases and Deaths by Type of Cancer in Women
Table 10.6: Estimated Age-Standardized Incidence and Mortality Rates Per 100,000 by World Area, 2008
Table 10.7: Worldwide CA 15-3 Sales, 2009-2019
Table 10.8: TPA Marker Sensitivity
Table 10.9: Worldwide CA 125 Sales, 2009-2019
Table 10.10: INFINITI Applications
Table 10.11: Global Revenue Forecasts for Cancer Marker Testing, 2008-2018
Table 11.1: Drug Testing Needs Tier I for Rapid Serum POCT in the Emergency Department
Table 11.2: Stat Urine Testing Drug Recommendations
Table 11.3: Selected POC Substance/Drug Abuse Testing Devices, 2011
Table 11.4: Selected POC Substance/Drug Abuse Testing Devices, OraSure, 2011
Table 11.5: Selected Target Substances and Drugs, 2011
Table 11.6: Global Revenue Forecasts for Substance Abuse Testing, 2008-2018
Table 12.1: Global Revenue Forecasts for Vitamin D Testing, 2008-2018
Table 14.1: Companion Biomarker Market Size, 2008-2018
Table 15.1: Worldwide Geographic Distribution of Total IVD Testing Market, 2012
Table 15.2: Top 13 Country IVD Testing Markets, 2012
Table 15.3: Company Market Share for IVD Testing Markets, 2012
Table 15.4: Global Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing, 2008-2018
Table 15.5: Global IVD High-Growth Markets Percentage of Revenues by Geographic Region, 2008-2018
Table 15.6: Global IVD High-Growth Markets Percentage of Revenues by Product Type, 2008-2018
Table 15.7: Summary of IVD High-Growth Market U.S., 2011
Table 15.8: Summary Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing U.S., 2008-2018
Table 15.9: U.S. Individual IVD High-Growth Markets Revenue Forecast, 2008-2018
Table 15.10: U.S. Individual IVD High-Growth Markets Percentage of Revenues by Product Type, 2008-2018
Table 15.11: Specific Cardiac Markers
Table 15.12: Cardiac Markers after Onset of Myocardial Infarction
Table 15.13: U.S. Cardiac Marker Revenue Forecasts, 2008-2018
Table 15.14: Market Share of Cardiac Marker Segment
Table 15.15: Summary Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing Europe, 2008-2018
Table 15.16: Europe: Individual IVD High-Growth Markets Revenue Forecast, 2008-2018
Table 15.17: Europe: Individual IVD High-Growth Markets Percentage of Revenues by Product Type, 2008-2018
Table 15.18: Summary Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing Brazil, 2008-2018
Table 15.19: Brazil: Individual IVD High-Growth Markets Revenue Forecast, 2008-2018
Table 15.20: Brazil: Individual IVD High-Growth Markets Percentage of Revenues by Product Type, 2008-2018
Table 15.21: Summary Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing Russia, 2008-2018
Table 15.22: Russia: Individual IVD High-Growth Markets Revenue Forecast, 2008-2018
Table 15.23: Russia: Individual IVD High-Growth Markets Percentage of Revenues by Product Type, 2008-2018
Table 15.24: Overview of Healthcare in India
Table 15.25: Population Projections India, 2000-2020
Table 15.26: Statistical Healthcare Data India
Table 15.27: Summary Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing India, 2008-2018
Table 15.28: India: Individual IVD High-Growth Markets Revenue Forecast, 2008-2018
Table 15.29: India: Individual IVD High-Growth Markets Percentage of Revenues by Product Type, 2008-2018
Table 15.30: Number of Healthcare Institutions According to Ownership China, 2010
Table 15.31: Total Number of Hospitals by Ranking China, 2010
Table 15.32: Disease Burden in China: Urban and Rural
Table 15.33: China Biotech Reagents Market
Table 15.34: Biotechnology Projects Between China and the West
Table 15.35: Summary Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing China, 2008-2018
Table 15.36: China: Individual IVD High-Growth Markets Revenue Forecast, 2008-2018
Table 15.37: China: Individual IVD High-Growth Markets Percentage of Revenues by Product Type, 2008-2018
Table 15.38: Summary Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing Other Asia, 2008-2018
Table 15.39: Other Asia: Individual IVD High-Growth Markets Revenue Forecast, 2008-2018
Table 15.40: Other Asia: Individual IVD High-Growth Markets Percentage of Revenues by Product Type, 2008-2018
Table 17.1: Medicare National Minimum Payment Amounts for Cervical Pathology Procedures
Table 18.1: New CPT Test Codes Introduced in 2008
Table 19.1: Employment of Clinical Laboratory Workers, 2006-2016
Table 21.1: Common Genotype Techniques
Table 22.1: Applications for Wireless LAN Technology
Table 22.2: Customized Reports Must Support CAP and JCAHO Requirements
Table 22.3: RALS-Plus Point of Care Market Share
Table 22.4: Applications of RALS Connectivity with POCT Devices
Table 23.1: Biochip Revenues and Growth Rates by Application, 2012 and 2018
Table 23.2: Total Biochip Market: Worldwide Revenue Forecasts, 2008-2018
Table 23.3: Total Biochip Market: U.S. Revenue Forecasts, 2008-2018
Table 24.1: Abaxis, Inc. Financial Figures—Net Sales by Business Sector, 2011-2013
Table 24.2: Abaxis, Inc. Financial Figures—Net Sales by Geographic Region, 2011-2013
Table 24.3: Abbott Laboratories Financial Figures—Net Sales by Business Sector, 2010-2012
Table 24.4: Abbott Laboratories Financial Figures—Net Sales by Geographic Region, 2010-2012
Table 24.5: Alere, Inc. Financial Figures—Net Sales by Business Sector, 2008-2012
Table 24.6: Alere, Inc. Financial Figures—Net Sales by Geographic Region, 2008-2012
Table 24.7: Bayer AG Financial Figures—Net Sales by Business Sector, 2009-2012
Table 24.8: Bayer AG Financial Figures—Net Sales by Geographic Region, 2009-2012
Table 24.9: Bio-Rad Laboratories, Inc. Financial Figures—Net Sales by Business Sector, 2009-2012
Table 24.10: Bio-Rad Laboratories, Inc. Financial Figures—Net Sales by Geographic Region, 2009-2010
Table 24.11: Johnson & Johnson Financial Figures—Net Sales by Major Medical and Diagnostics Businesses, 2010-2012
Table 24.12: Quidel Product Sales Distribution and Sales, 2010-2012
Table 24.13: Danaher Corporation Financial Figures—Net Sales by Business Sector, 2009-2012
Table 24.14: Danaher Corporation Financial Figures—Net Sales by Geographic Region, 2010-2012
Table 24.15: Roche Group Financial Figures—Net Sales by Business Sector, 2009-2012
Table 24.16: Roche Group Financial Figures—Net Sales by Geographic Region, 2010-2012
Table 24.17: Roche Group Financial Figures—Net Sales by Sub-Division, 2011 and 2012

Note: Product cover images may vary from those shown

- A Menarini Diagnostics
- Abaxis, Inc
- Abbott Laboratories
- Accurex Biomedical Pvt Ltd
- Adeza Biomedical Corporation (Hologic)
- Agilent Technologies, Inc
- Alere, Inc
- Ambri Ltd
- American Bio Medica Corporation
- Ani Biotech Oy Ltd
- Applied Spectral Imaging
- Avitar, Inc
- Axis-Shield Plc
- Bayer Corporation
- Beckman Coulter (now part of Danaher)
- Becton, Dickinson and Company
- Bio-Rad Laboratories, Inc
- Biomerica, Inc
- Calypte Biomedical Corporation
- Chembio Diagnostics, Inc
- Cozart Bioscience Ltd
- diaDexus, LLC
- Denka Seiken Co, Ltd
- EY Laboratories, Inc
- Enterix, Inc (Subsidiary of Quest Diagnostics)
- Genetix (Molecular Devices)
- Genzyme Diagnostics
- Hologic Gen Probe
- Instrumentation Laboratory (IL)/Werfen Group
- Jiangnan Biotech
- Johnson & Johnson
- Kyowa Medex Co, Ltd
- LifeAssays AB
- LifeScan
- Matritech
- Medix Biochemica
- Meretek Diagnostics Group (Otsuka Pharmaceutical, Inc)
- Meridian Bioscience
- Myriad Genetics, Inc
- NOVA Biomedical
- OraSure
- Pheromone Sciences Corporation
- Polymedco, Inc
- Polymer Technology Systems, Inc
- QIAGEN NV
- Quest Diagnostics, Inc
- Quidel Corporation
- Radiometer Medical
- Roche Diagnostics
- Shanghai SIIC Kehua Biotech Co, Ltd (Kehua Biotech)
- Shionogi & Co, Ltd
- Siemens Healthcare Diagnostics
- Spectral Diagnostics, Inc
- Trinity Biotech Plc
- Väsamed, Inc

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

ALSO AVAILABLE

RELATED PRODUCTS

Our Clients

Our clients' logos